

Global Nonvalvular Atrial Fibrillation Drugs Market Research Report 2023

<https://marketpublishers.com/r/G1643305D6EEEN.html>

Date: October 2023

Pages: 113

Price: US\$ 2,900.00 (Single User License)

ID: G1643305D6EEEN

Abstracts

This report aims to provide a comprehensive presentation of the global market for Nonvalvular Atrial Fibrillation Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nonvalvular Atrial Fibrillation Drugs.

The Nonvalvular Atrial Fibrillation Drugs market size, estimations, and forecasts are provided in terms of and revenue (\$ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Nonvalvular Atrial Fibrillation Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Nonvalvular Atrial Fibrillation Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

By Company

Amneal Pharma

Cipla (InvaGen)

Orion Corporation

Bristol Myers Squibb

UPSHER SMITH LABS (Sawai Pharmaceutical Co.,Ltd)

Taro Pharmaceutical Industries Ltd.

CTX Life Sciences

Mehta API Pvt

Amtec Health Care Pvt

Polpharma

Apotex Pharmachem

Dr. Reddy's

Jubilant Pharma

Vasudha Pharma Chem

Tapi Teva

Metrochem

Lee Pharma

Qilu Pharmaceutical

Shanghai Pharmaceutical Group

Henan Zhongjie Pharmaceutical

Tianyu Pharm

Jinan Jianfeng Chemical

Hisun

Segment by Type

Warfarin

Dabigatran Etexilate Mesylate

Xarelto

Apixaban

Segment by Application

????

????

????

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Nonvalvular Atrial Fibrillation Drugs companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product

introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Nonvalvular Atrial Fibrillation Drugs Market Size Growth Rate by Type:
2018 VS 2022 VS 2029

1.2.2 Warfarin

1.2.3 Dabigatran Etxilate Mesylate

1.2.4 Xarelto

1.2.5 Apixaban

1.3 Market by Application

1.3.1 Global Nonvalvular Atrial Fibrillation Drugs Market Growth by Application: 2018
VS 2022 VS 2029

1.3.2 ?????

1.3.3 ?????

1.3.4 ?????

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Nonvalvular Atrial Fibrillation Drugs Market Perspective (2018-2029)

2.2 Nonvalvular Atrial Fibrillation Drugs Growth Trends by Region

2.2.1 Global Nonvalvular Atrial Fibrillation Drugs Market Size by Region: 2018 VS
2022 VS 2029

2.2.2 Nonvalvular Atrial Fibrillation Drugs Historic Market Size by Region (2018-2023)

2.2.3 Nonvalvular Atrial Fibrillation Drugs Forecasted Market Size by Region
(2024-2029)

2.3 Nonvalvular Atrial Fibrillation Drugs Market Dynamics

2.3.1 Nonvalvular Atrial Fibrillation Drugs Industry Trends

2.3.2 Nonvalvular Atrial Fibrillation Drugs Market Drivers

2.3.3 Nonvalvular Atrial Fibrillation Drugs Market Challenges

2.3.4 Nonvalvular Atrial Fibrillation Drugs Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Nonvalvular Atrial Fibrillation Drugs Players by Revenue

3.1.1 Global Top Nonvalvular Atrial Fibrillation Drugs Players by Revenue (2018-2023)

3.1.2 Global Nonvalvular Atrial Fibrillation Drugs Revenue Market Share by Players (2018-2023)

3.2 Global Nonvalvular Atrial Fibrillation Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Nonvalvular Atrial Fibrillation Drugs Revenue

3.4 Global Nonvalvular Atrial Fibrillation Drugs Market Concentration Ratio

3.4.1 Global Nonvalvular Atrial Fibrillation Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Nonvalvular Atrial Fibrillation Drugs Revenue in 2022

3.5 Nonvalvular Atrial Fibrillation Drugs Key Players Head office and Area Served

3.6 Key Players Nonvalvular Atrial Fibrillation Drugs Product Solution and Service

3.7 Date of Enter into Nonvalvular Atrial Fibrillation Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 NONVALVULAR ATRIAL FIBRILLATION DRUGS BREAKDOWN DATA BY TYPE

4.1 Global Nonvalvular Atrial Fibrillation Drugs Historic Market Size by Type (2018-2023)

4.2 Global Nonvalvular Atrial Fibrillation Drugs Forecasted Market Size by Type (2024-2029)

5 NONVALVULAR ATRIAL FIBRILLATION DRUGS BREAKDOWN DATA BY APPLICATION

5.1 Global Nonvalvular Atrial Fibrillation Drugs Historic Market Size by Application (2018-2023)

5.2 Global Nonvalvular Atrial Fibrillation Drugs Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Nonvalvular Atrial Fibrillation Drugs Market Size (2018-2029)

6.2 North America Nonvalvular Atrial Fibrillation Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Nonvalvular Atrial Fibrillation Drugs Market Size by Country (2018-2023)

6.4 North America Nonvalvular Atrial Fibrillation Drugs Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7 EUROPE

7.1 Europe Nonvalvular Atrial Fibrillation Drugs Market Size (2018-2029)

7.2 Europe Nonvalvular Atrial Fibrillation Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Nonvalvular Atrial Fibrillation Drugs Market Size by Country (2018-2023)

7.4 Europe Nonvalvular Atrial Fibrillation Drugs Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Nonvalvular Atrial Fibrillation Drugs Market Size (2018-2029)

8.2 Asia-Pacific Nonvalvular Atrial Fibrillation Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Nonvalvular Atrial Fibrillation Drugs Market Size by Region (2018-2023)

8.4 Asia-Pacific Nonvalvular Atrial Fibrillation Drugs Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 LATIN AMERICA

9.1 Latin America Nonvalvular Atrial Fibrillation Drugs Market Size (2018-2029)

9.2 Latin America Nonvalvular Atrial Fibrillation Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Nonvalvular Atrial Fibrillation Drugs Market Size by Country

(2018-2023)

9.4 Latin America Nonvalvular Atrial Fibrillation Drugs Market Size by Country

(2024-2029)

9.5 Mexico

9.6 Brazil

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Nonvalvular Atrial Fibrillation Drugs Market Size (2018-2029)

10.2 Middle East & Africa Nonvalvular Atrial Fibrillation Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Nonvalvular Atrial Fibrillation Drugs Market Size by Country (2018-2023)

10.4 Middle East & Africa Nonvalvular Atrial Fibrillation Drugs Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 KEY PLAYERS PROFILES

11.1 Amneal Pharma

11.1.1 Amneal Pharma Company Detail

11.1.2 Amneal Pharma Business Overview

11.1.3 Amneal Pharma Nonvalvular Atrial Fibrillation Drugs Introduction

11.1.4 Amneal Pharma Revenue in Nonvalvular Atrial Fibrillation Drugs Business

(2018-2023)

11.1.5 Amneal Pharma Recent Development

11.2 Cipla (InvaGen)

11.2.1 Cipla (InvaGen) Company Detail

11.2.2 Cipla (InvaGen) Business Overview

11.2.3 Cipla (InvaGen) Nonvalvular Atrial Fibrillation Drugs Introduction

11.2.4 Cipla (InvaGen) Revenue in Nonvalvular Atrial Fibrillation Drugs Business

(2018-2023)

11.2.5 Cipla (InvaGen) Recent Development

11.3 Orion Corporation

11.3.1 Orion Corporation Company Detail

11.3.2 Orion Corporation Business Overview

11.3.3 Orion Corporation Nonvalvular Atrial Fibrillation Drugs Introduction

11.3.4 Orion Corporation Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

11.3.5 Orion Corporation Recent Development

11.4 Bristol Myers Squibb

11.4.1 Bristol Myers Squibb Company Detail

11.4.2 Bristol Myers Squibb Business Overview

11.4.3 Bristol Myers Squibb Nonvalvular Atrial Fibrillation Drugs Introduction

11.4.4 Bristol Myers Squibb Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

11.4.5 Bristol Myers Squibb Recent Development

11.5 UPSHER SMITH LABS (Sawai Pharmaceutical Co.,Ltd)

11.5.1 UPSHER SMITH LABS (Sawai Pharmaceutical Co.,Ltd) Company Detail

11.5.2 UPSHER SMITH LABS (Sawai Pharmaceutical Co.,Ltd) Business Overview

11.5.3 UPSHER SMITH LABS (Sawai Pharmaceutical Co.,Ltd) Nonvalvular Atrial Fibrillation Drugs Introduction

11.5.4 UPSHER SMITH LABS (Sawai Pharmaceutical Co.,Ltd) Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

11.5.5 UPSHER SMITH LABS (Sawai Pharmaceutical Co.,Ltd) Recent Development

11.6 Taro Pharmaceutical Industries Ltd.

11.6.1 Taro Pharmaceutical Industries Ltd. Company Detail

11.6.2 Taro Pharmaceutical Industries Ltd. Business Overview

11.6.3 Taro Pharmaceutical Industries Ltd. Nonvalvular Atrial Fibrillation Drugs Introduction

11.6.4 Taro Pharmaceutical Industries Ltd. Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

11.6.5 Taro Pharmaceutical Industries Ltd. Recent Development

11.7 CTX Life Sciences

11.7.1 CTX Life Sciences Company Detail

11.7.2 CTX Life Sciences Business Overview

11.7.3 CTX Life Sciences Nonvalvular Atrial Fibrillation Drugs Introduction

11.7.4 CTX Life Sciences Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

11.7.5 CTX Life Sciences Recent Development

11.8 Mehta API Pvt

11.8.1 Mehta API Pvt Company Detail

11.8.2 Mehta API Pvt Business Overview

11.8.3 Mehta API Pvt Nonvalvular Atrial Fibrillation Drugs Introduction

11.8.4 Mehta API Pvt Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

- 11.8.5 Mehta API Pvt Recent Development
- 11.9 Amtec Health Care Pvt
 - 11.9.1 Amtec Health Care Pvt Company Detail
 - 11.9.2 Amtec Health Care Pvt Business Overview
 - 11.9.3 Amtec Health Care Pvt Nonvalvular Atrial Fibrillation Drugs Introduction
 - 11.9.4 Amtec Health Care Pvt Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)
 - 11.9.5 Amtec Health Care Pvt Recent Development
- 11.10 Polpharma
 - 11.10.1 Polpharma Company Detail
 - 11.10.2 Polpharma Business Overview
 - 11.10.3 Polpharma Nonvalvular Atrial Fibrillation Drugs Introduction
 - 11.10.4 Polpharma Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)
 - 11.10.5 Polpharma Recent Development
- 11.11 Apotex Pharmachem
 - 11.11.1 Apotex Pharmachem Company Detail
 - 11.11.2 Apotex Pharmachem Business Overview
 - 11.11.3 Apotex Pharmachem Nonvalvular Atrial Fibrillation Drugs Introduction
 - 11.11.4 Apotex Pharmachem Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)
 - 11.11.5 Apotex Pharmachem Recent Development
- 11.12 Dr. Reddy's
 - 11.12.1 Dr. Reddy's Company Detail
 - 11.12.2 Dr. Reddy's Business Overview
 - 11.12.3 Dr. Reddy's Nonvalvular Atrial Fibrillation Drugs Introduction
 - 11.12.4 Dr. Reddy's Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)
 - 11.12.5 Dr. Reddy's Recent Development
- 11.13 Jubilant Pharma
 - 11.13.1 Jubilant Pharma Company Detail
 - 11.13.2 Jubilant Pharma Business Overview
 - 11.13.3 Jubilant Pharma Nonvalvular Atrial Fibrillation Drugs Introduction
 - 11.13.4 Jubilant Pharma Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)
 - 11.13.5 Jubilant Pharma Recent Development
- 11.14 Vasudha Pharma Chem
 - 11.14.1 Vasudha Pharma Chem Company Detail
 - 11.14.2 Vasudha Pharma Chem Business Overview

- 11.14.3 Vasudha Pharma Chem Nonvalvular Atrial Fibrillation Drugs Introduction
- 11.14.4 Vasudha Pharma Chem Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)
- 11.14.5 Vasudha Pharma Chem Recent Development
- 11.15 Tapi Teva
 - 11.15.1 Tapi Teva Company Detail
 - 11.15.2 Tapi Teva Business Overview
 - 11.15.3 Tapi Teva Nonvalvular Atrial Fibrillation Drugs Introduction
 - 11.15.4 Tapi Teva Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)
 - 11.15.5 Tapi Teva Recent Development
- 11.16 Metrochem
 - 11.16.1 Metrochem Company Detail
 - 11.16.2 Metrochem Business Overview
 - 11.16.3 Metrochem Nonvalvular Atrial Fibrillation Drugs Introduction
 - 11.16.4 Metrochem Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)
 - 11.16.5 Metrochem Recent Development
- 11.17 Lee Pharma
 - 11.17.1 Lee Pharma Company Detail
 - 11.17.2 Lee Pharma Business Overview
 - 11.17.3 Lee Pharma Nonvalvular Atrial Fibrillation Drugs Introduction
 - 11.17.4 Lee Pharma Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)
 - 11.17.5 Lee Pharma Recent Development
- 11.18 Qilu Pharmaceutical
 - 11.18.1 Qilu Pharmaceutical Company Detail
 - 11.18.2 Qilu Pharmaceutical Business Overview
 - 11.18.3 Qilu Pharmaceutical Nonvalvular Atrial Fibrillation Drugs Introduction
 - 11.18.4 Qilu Pharmaceutical Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)
 - 11.18.5 Qilu Pharmaceutical Recent Development
- 11.19 Shanghai Pharmaceutical Group
 - 11.19.1 Shanghai Pharmaceutical Group Company Detail
 - 11.19.2 Shanghai Pharmaceutical Group Business Overview
 - 11.19.3 Shanghai Pharmaceutical Group Nonvalvular Atrial Fibrillation Drugs Introduction
 - 11.19.4 Shanghai Pharmaceutical Group Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

- 11.19.5 Shanghai Pharmaceutical Group Recent Development
- 11.20 Henan Zhongjie Pharmaceutical
 - 11.20.1 Henan Zhongjie Pharmaceutical Company Detail
 - 11.20.2 Henan Zhongjie Pharmaceutical Business Overview
 - 11.20.3 Henan Zhongjie Pharmaceutical Nonvalvular Atrial Fibrillation Drugs Introduction
 - 11.20.4 Henan Zhongjie Pharmaceutical Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)
 - 11.20.5 Henan Zhongjie Pharmaceutical Recent Development
- 11.21 Tianyu Pharm
 - 11.21.1 Tianyu Pharm Company Detail
 - 11.21.2 Tianyu Pharm Business Overview
 - 11.21.3 Tianyu Pharm Nonvalvular Atrial Fibrillation Drugs Introduction
 - 11.21.4 Tianyu Pharm Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)
 - 11.21.5 Tianyu Pharm Recent Development
- 11.22 Jinan Jianfeng Chemical
 - 11.22.1 Jinan Jianfeng Chemical Company Detail
 - 11.22.2 Jinan Jianfeng Chemical Business Overview
 - 11.22.3 Jinan Jianfeng Chemical Nonvalvular Atrial Fibrillation Drugs Introduction
 - 11.22.4 Jinan Jianfeng Chemical Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)
 - 11.22.5 Jinan Jianfeng Chemical Recent Development
- 11.23 Hisun
 - 11.23.1 Hisun Company Detail
 - 11.23.2 Hisun Business Overview
 - 11.23.3 Hisun Nonvalvular Atrial Fibrillation Drugs Introduction
 - 11.23.4 Hisun Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)
 - 11.23.5 Hisun Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

- 13.1 Research Methodology
 - 13.1.1 Methodology/Research Approach
 - 13.1.2 Data Source
- 13.2 Disclaimer

13.3 Author Details

List Of Tables

LIST OF TABLES

- Table 1. Global Nonvalvular Atrial Fibrillation Drugs Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029
- Table 2. Key Players of Warfarin
- Table 3. Key Players of Dabigatran Etexilate Mesylate
- Table 4. Key Players of Xarelto
- Table 5. Key Players of Apixaban
- Table 6. Global Nonvalvular Atrial Fibrillation Drugs Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029
- Table 7. Global Nonvalvular Atrial Fibrillation Drugs Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029
- Table 8. Global Nonvalvular Atrial Fibrillation Drugs Market Size by Region (2018-2023) & (US\$ Million)
- Table 9. Global Nonvalvular Atrial Fibrillation Drugs Market Share by Region (2018-2023)
- Table 10. Global Nonvalvular Atrial Fibrillation Drugs Forecasted Market Size by Region (2024-2029) & (US\$ Million)
- Table 11. Global Nonvalvular Atrial Fibrillation Drugs Market Share by Region (2024-2029)
- Table 12. Nonvalvular Atrial Fibrillation Drugs Market Trends
- Table 13. Nonvalvular Atrial Fibrillation Drugs Market Drivers
- Table 14. Nonvalvular Atrial Fibrillation Drugs Market Challenges
- Table 15. Nonvalvular Atrial Fibrillation Drugs Market Restraints
- Table 16. Global Nonvalvular Atrial Fibrillation Drugs Revenue by Players (2018-2023) & (US\$ Million)
- Table 17. Global Nonvalvular Atrial Fibrillation Drugs Market Share by Players (2018-2023)
- Table 18. Global Top Nonvalvular Atrial Fibrillation Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonvalvular Atrial Fibrillation Drugs as of 2022)
- Table 19. Ranking of Global Top Nonvalvular Atrial Fibrillation Drugs Companies by Revenue (US\$ Million) in 2022
- Table 20. Global 5 Largest Players Market Share by Nonvalvular Atrial Fibrillation Drugs Revenue (CR5 and HHI) & (2018-2023)
- Table 21. Key Players Headquarters and Area Served
- Table 22. Key Players Nonvalvular Atrial Fibrillation Drugs Product Solution and Service

Table 23. Date of Enter into Nonvalvular Atrial Fibrillation Drugs Market

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Nonvalvular Atrial Fibrillation Drugs Market Size by Type (2018-2023) & (US\$ Million)

Table 26. Global Nonvalvular Atrial Fibrillation Drugs Revenue Market Share by Type (2018-2023)

Table 27. Global Nonvalvular Atrial Fibrillation Drugs Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 28. Global Nonvalvular Atrial Fibrillation Drugs Revenue Market Share by Type (2024-2029)

Table 29. Global Nonvalvular Atrial Fibrillation Drugs Market Size by Application (2018-2023) & (US\$ Million)

Table 30. Global Nonvalvular Atrial Fibrillation Drugs Revenue Market Share by Application (2018-2023)

Table 31. Global Nonvalvular Atrial Fibrillation Drugs Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 32. Global Nonvalvular Atrial Fibrillation Drugs Revenue Market Share by Application (2024-2029)

Table 33. North America Nonvalvular Atrial Fibrillation Drugs Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 34. North America Nonvalvular Atrial Fibrillation Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 35. North America Nonvalvular Atrial Fibrillation Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 36. Europe Nonvalvular Atrial Fibrillation Drugs Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 37. Europe Nonvalvular Atrial Fibrillation Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 38. Europe Nonvalvular Atrial Fibrillation Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 39. Asia-Pacific Nonvalvular Atrial Fibrillation Drugs Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 40. Asia-Pacific Nonvalvular Atrial Fibrillation Drugs Market Size by Region (2018-2023) & (US\$ Million)

Table 41. Asia-Pacific Nonvalvular Atrial Fibrillation Drugs Market Size by Region (2024-2029) & (US\$ Million)

Table 42. Latin America Nonvalvular Atrial Fibrillation Drugs Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 43. Latin America Nonvalvular Atrial Fibrillation Drugs Market Size by Country

(2018-2023) & (US\$ Million)

Table 44. Latin America Nonvalvular Atrial Fibrillation Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 45. Middle East & Africa Nonvalvular Atrial Fibrillation Drugs Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 46. Middle East & Africa Nonvalvular Atrial Fibrillation Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 47. Middle East & Africa Nonvalvular Atrial Fibrillation Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 48. Amneal Pharma Company Detail

Table 49. Amneal Pharma Business Overview

Table 50. Amneal Pharma Nonvalvular Atrial Fibrillation Drugs Product

Table 51. Amneal Pharma Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)

Table 52. Amneal Pharma Recent Development

Table 53. Cipla (InvaGen) Company Detail

Table 54. Cipla (InvaGen) Business Overview

Table 55. Cipla (InvaGen) Nonvalvular Atrial Fibrillation Drugs Product

Table 56. Cipla (InvaGen) Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)

Table 57. Cipla (InvaGen) Recent Development

Table 58. Orion Corporation Company Detail

Table 59. Orion Corporation Business Overview

Table 60. Orion Corporation Nonvalvular Atrial Fibrillation Drugs Product

Table 61. Orion Corporation Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)

Table 62. Orion Corporation Recent Development

Table 63. Bristol Myers Squibb Company Detail

Table 64. Bristol Myers Squibb Business Overview

Table 65. Bristol Myers Squibb Nonvalvular Atrial Fibrillation Drugs Product

Table 66. Bristol Myers Squibb Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)

Table 67. Bristol Myers Squibb Recent Development

Table 68. UPSHER SMITH LABS (Sawai Pharmaceutical Co.,Ltd) Company Detail

Table 69. UPSHER SMITH LABS (Sawai Pharmaceutical Co.,Ltd) Business Overview

Table 70. UPSHER SMITH LABS (Sawai Pharmaceutical Co.,Ltd) Nonvalvular Atrial Fibrillation Drugs Product

Table 71. UPSHER SMITH LABS (Sawai Pharmaceutical Co.,Ltd) Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)

- Table 72. UPSHER SMITH LABS (Sawai Pharmaceutical Co.,Ltd) Recent Development
- Table 73. Taro Pharmaceutical Industries Ltd. Company Detail
- Table 74. Taro Pharmaceutical Industries Ltd. Business Overview
- Table 75. Taro Pharmaceutical Industries Ltd. Nonvalvular Atrial Fibrillation Drugs Product
- Table 76. Taro Pharmaceutical Industries Ltd. Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)
- Table 77. Taro Pharmaceutical Industries Ltd. Recent Development
- Table 78. CTX Life Sciences Company Detail
- Table 79. CTX Life Sciences Business Overview
- Table 80. CTX Life Sciences Nonvalvular Atrial Fibrillation Drugs Product
- Table 81. CTX Life Sciences Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)
- Table 82. CTX Life Sciences Recent Development
- Table 83. Mehta API Pvt Company Detail
- Table 84. Mehta API Pvt Business Overview
- Table 85. Mehta API Pvt Nonvalvular Atrial Fibrillation Drugs Product
- Table 86. Mehta API Pvt Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)
- Table 87. Mehta API Pvt Recent Development
- Table 88. Amtec Health Care Pvt Company Detail
- Table 89. Amtec Health Care Pvt Business Overview
- Table 90. Amtec Health Care Pvt Nonvalvular Atrial Fibrillation Drugs Product
- Table 91. Amtec Health Care Pvt Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)
- Table 92. Amtec Health Care Pvt Recent Development
- Table 93. Polpharma Company Detail
- Table 94. Polpharma Business Overview
- Table 95. Polpharma Nonvalvular Atrial Fibrillation Drugs Product
- Table 96. Polpharma Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)
- Table 97. Polpharma Recent Development
- Table 98. Apotex Pharmachem Company Detail
- Table 99. Apotex Pharmachem Business Overview
- Table 100. Apotex Pharmachem Nonvalvular Atrial Fibrillation Drugs Product
- Table 101. Apotex Pharmachem Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)
- Table 102. Apotex Pharmachem Recent Development
- Table 103. Dr. Reddy's Company Detail

- Table 104. Dr. Reddy's Business Overview
- Table 105. Dr. Reddy's Nonvalvular Atrial Fibrillation Drugs Product
- Table 106. Dr. Reddy's Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)
- Table 107. Dr. Reddy's Recent Development
- Table 108. Jubilant Pharma Company Detail
- Table 109. Jubilant Pharma Business Overview
- Table 110. Jubilant Pharma Nonvalvular Atrial Fibrillation Drugs Product
- Table 111. Jubilant Pharma Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)
- Table 112. Jubilant Pharma Recent Development
- Table 113. Vasudha Pharma Chem Company Detail
- Table 114. Vasudha Pharma Chem Business Overview
- Table 115. Vasudha Pharma Chem Nonvalvular Atrial Fibrillation Drugs Product
- Table 116. Vasudha Pharma Chem Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)
- Table 117. Vasudha Pharma Chem Recent Development
- Table 118. Tapi Teva Company Detail
- Table 119. Tapi Teva Business Overview
- Table 120. Tapi Teva Nonvalvular Atrial Fibrillation Drugs Product
- Table 121. Tapi Teva Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)
- Table 122. Tapi Teva Recent Development
- Table 123. Metrochem Company Detail
- Table 124. Metrochem Business Overview
- Table 125. Metrochem Nonvalvular Atrial Fibrillation Drugs Product
- Table 126. Metrochem Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)
- Table 127. Metrochem Recent Development
- Table 128. Lee Pharma Company Detail
- Table 129. Lee Pharma Business Overview
- Table 130. Lee Pharma Nonvalvular Atrial Fibrillation Drugs Product
- Table 131. Lee Pharma Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)
- Table 132. Lee Pharma Recent Development
- Table 133. Qilu Pharmaceutical Company Detail
- Table 134. Qilu Pharmaceutical Business Overview
- Table 135. Qilu Pharmaceutical Nonvalvular Atrial Fibrillation Drugs Product
- Table 136. Qilu Pharmaceutical Revenue in Nonvalvular Atrial Fibrillation Drugs

Business (2018-2023) & (US\$ Million)

Table 137. Qilu Pharmaceutical Recent Development

Table 138. Shanghai Pharmaceutical Group Company Detail

Table 139. Shanghai Pharmaceutical Group Business Overview

Table 140. Shanghai Pharmaceutical Group Nonvalvular Atrial Fibrillation Drugs Product

Table 141. Shanghai Pharmaceutical Group Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)

Table 142. Shanghai Pharmaceutical Group Recent Development

Table 143. Henan Zhongjie Pharmaceutical Company Detail

Table 144. Henan Zhongjie Pharmaceutical Business Overview

Table 145. Henan Zhongjie Pharmaceutical Nonvalvular Atrial Fibrillation Drugs Product

Table 146. Henan Zhongjie Pharmaceutical Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)

Table 147. Henan Zhongjie Pharmaceutical Recent Development

Table 148. Tianyu Pharm Company Detail

Table 149. Tianyu Pharm Business Overview

Table 150. Tianyu Pharm Nonvalvular Atrial Fibrillation Drugs Product

Table 151. Tianyu Pharm Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)

Table 152. Tianyu Pharm Recent Development

Table 153. Jinan Jianfeng Chemical Company Detail

Table 154. Jinan Jianfeng Chemical Business Overview

Table 155. Jinan Jianfeng Chemical Nonvalvular Atrial Fibrillation Drugs Product

Table 156. Jinan Jianfeng Chemical Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)

Table 157. Jinan Jianfeng Chemical Recent Development

Table 158. Hisun Company Detail

Table 159. Hisun Business Overview

Table 160. Hisun Nonvalvular Atrial Fibrillation Drugs Product

Table 161. Hisun Revenue in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023) & (US\$ Million)

Table 162. Hisun Recent Development

Table 163. Research Programs/Design for This Report

Table 164. Key Data Information from Secondary Sources

Table 165. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Nonvalvular Atrial Fibrillation Drugs Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 2. Global Nonvalvular Atrial Fibrillation Drugs Market Share by Type: 2022 VS 2029

Figure 3. Warfarin Features

Figure 4. Dabigatran Etexilate Mesylate Features

Figure 5. Xarelto Features

Figure 6. Apixaban Features

Figure 7. Global Nonvalvular Atrial Fibrillation Drugs Market Size Comparison by Application (2023-2029) & (US\$ Million)

Figure 8. Global Nonvalvular Atrial Fibrillation Drugs Market Share by Application: 2022 VS 2029

Figure 9. ???? Case Studies

Figure 10. ???? Case Studies

Figure 11. ???? Case Studies

Figure 12. Nonvalvular Atrial Fibrillation Drugs Report Years Considered

Figure 13. Global Nonvalvular Atrial Fibrillation Drugs Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 14. Global Nonvalvular Atrial Fibrillation Drugs Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 15. Global Nonvalvular Atrial Fibrillation Drugs Market Share by Region: 2022 VS 2029

Figure 16. Global Nonvalvular Atrial Fibrillation Drugs Market Share by Players in 2022

Figure 17. Global Top Nonvalvular Atrial Fibrillation Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonvalvular Atrial Fibrillation Drugs as of 2022)

Figure 18. The Top 10 and 5 Players Market Share by Nonvalvular Atrial Fibrillation Drugs Revenue in 2022

Figure 19. North America Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 20. North America Nonvalvular Atrial Fibrillation Drugs Market Share by Country (2018-2029)

Figure 21. United States Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 22. Canada Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth

(2018-2029) & (US\$ Million)

Figure 23. Europe Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. Europe Nonvalvular Atrial Fibrillation Drugs Market Share by Country (2018-2029)

Figure 25. Germany Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. France Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. U.K. Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. Italy Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Russia Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Nordic Countries Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Asia-Pacific Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Asia-Pacific Nonvalvular Atrial Fibrillation Drugs Market Share by Region (2018-2029)

Figure 33. China Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. Japan Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. South Korea Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. Southeast Asia Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. India Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. Australia Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Latin America Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Latin America Nonvalvular Atrial Fibrillation Drugs Market Share by Country (2018-2029)

Figure 41. Mexico Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. Brazil Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 43. Middle East & Africa Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. Middle East & Africa Nonvalvular Atrial Fibrillation Drugs Market Share by Country (2018-2029)

Figure 45. Turkey Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Saudi Arabia Nonvalvular Atrial Fibrillation Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. Amneal Pharma Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

Figure 48. Cipla (InvaGen) Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

Figure 49. Orion Corporation Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

Figure 50. Bristol Myers Squibb Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

Figure 51. UPSHER SMITH LABS (Sawai Pharmaceutical Co.,Ltd) Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

Figure 52. Taro Pharmaceutical Industries Ltd. Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

Figure 53. CTX Life Sciences Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

Figure 54. Mehta API Pvt Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

Figure 55. Amtec Health Care Pvt Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

Figure 56. Polpharma Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

Figure 57. Apotex Pharmachem Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

Figure 58. Dr. Reddy's Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

Figure 59. Jubilant Pharma Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

Figure 60. Vasudha Pharma Chem Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business (2018-2023)

Figure 61. Tapi Teva Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs

Business (2018-2023)

Figure 62. Metrochem Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs

Business (2018-2023)

Figure 63. Lee Pharma Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs

Business (2018-2023)

Figure 64. Qilu Pharmaceutical Revenue Growth Rate in Nonvalvular Atrial Fibrillation
Drugs Business (2018-2023)

Figure 65. Shanghai Pharmaceutical Group Revenue Growth Rate in Nonvalvular Atrial
Fibrillation Drugs Business (2018-2023)

Figure 66. Henan Zhongjie Pharmaceutical Revenue Growth Rate in Nonvalvular Atrial
Fibrillation Drugs Business (2018-2023)

Figure 67. Tianyu Pharm Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs
Business (2018-2023)

Figure 68. Jinan Jianfeng Chemical Revenue Growth Rate in Nonvalvular Atrial
Fibrillation Drugs Business (2018-2023)

Figure 69. Hisun Revenue Growth Rate in Nonvalvular Atrial Fibrillation Drugs Business
(2018-2023)

Figure 70. Bottom-up and Top-down Approaches for This Report

Figure 71. Data Triangulation

Figure 72. Key Executives Interviewed

I would like to order

Product name: Global Nonvalvular Atrial Fibrillation Drugs Market Research Report 2023

Product link: <https://marketpublishers.com/r/G1643305D6EEEN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1643305D6EEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970